Holen Sie sich die Stockscreener-App
32.18
1.22%
0.53
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics completes enrollment in trial of VK2735 - Yahoo Finance
Will Viking Therapeutics’ New CCO Reframe VKTX’s Obesity Strategy Amid Intensifying GLP-1 Competition? - Sahm
Viking Therapeutics: InvestingPro’s overvalued call proved right amid volatility By Investing.com - Investing.com Nigeria
Can Viking Therapeutics Inc. stock maintain growth trajectory2025 Top Gainers & Safe Capital Allocation Plans - ulpravda.ru
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Finviz
Brokers suggest investing in Viking Therapeutics (VKTX): Read this before placing a bet - MSN
How Viking Therapeutics Inc. stock performs during Fed tightening cyclesPortfolio Performance Summary & Free Daily Entry Point Trade Alerts - ulpravda.ru
Will Viking Therapeutics Inc. stock outperform growth indexes2025 Fundamental Recap & Low Drawdown Momentum Ideas - ulpravda.ru
Viking Therapeutics (VKTX) Completes Enrollment for Key Metaboli - GuruFocus
Viking Therapeutics completes enrollment in obesity drug maintenance study By Investing.com - Investing.com Australia
Viking Therapeutics completes enrollment in obesity drug maintenance study - Investing.com
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity - Nasdaq
Viking Therapeutics Charts Commercial Course with Key Appointment and Upcoming Investor Presentation - AD HOC NEWS
Viking Therapeutics Faces Headwinds Amid Commercial Push and Insider Sales - AD HOC NEWS
Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms - Stocktwits
Viking Therapeutics: A Tale of Strategic Hiring and Insider Sales - AD HOC NEWS
Viking Therapeutics Hires Neil Aubuchon as Chief Commercial Officer - Contract Pharma
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer By Investing.com - Investing.com Nigeria
Viking Therapeutics appoints Neil Aubuchon as chief commercial officer - Investing.com India
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer - PR Newswire
Why Viking Therapeutics Stock Crashed Today - AOL.com
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Viking Therapeutics Faces Scrutiny Amid Insider Sales and Key Industry Event - AD HOC NEWS
Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today - Sahm
Here's What $100 Invested in Viking Therapeutics a Decade Ago Would Amount to Now - Bitget
Examining the Latest Short Interest in Viking Therapeutics Inc - Bitget
Looking Into Viking Therapeutics Inc's Recent Short Interest - Sahm
Insider Sales and Market Competition Weigh on Viking Therapeutics Shares - AD HOC NEWS
Insider Sell Alert: Matthew Foehr Sells 16,000 Shares of Viking Therapeutics Inc (VKTX) - GuruFocus
Viking Therapeutics Insider Sold Shares Worth $7,692,121, According to a Recent SEC Filing - MarketScreener
Viking Therapeutics Insider Sold Shares Worth $1,896,969, According to a Recent SEC Filing - MarketScreener
Leadership Stock Sales Cast Shadow Over Viking Therapeutics’ Prospects - AD HOC NEWS
What drives Viking Therapeutics Inc 1VT stock pricePrice Action Analysis & Low Risk Wealth Building - earlytimes.in
Viking Therapeutics stock suffers worst day in over 4 months as top execs dump shares — Novo’s $149 Wegovy move looms - MSN
Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock - MarketBeat
Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock - MarketBeat
Viking Therapeutics CEO Lian sells $7.69m in shares By Investing.com - Investing.com Nigeria
Viking therapeutics COO Mancini sells $1.9 million in stock By Investing.com - Investing.com Nigeria
Viking Therapeutics CEO Lian sells $7.69m in shares - Investing.com
Viking therapeutics COO Mancini sells $1.9 million in stock - Investing.com
Viking Therapeutics director Foehr sells $561,694 in shares By Investing.com - Investing.com South Africa
Viking Therapeutics director Foehr sells $561,694 in shares - Investing.com
Viking therapeutics CFO Zante sells $1.89m in shares By Investing.com - Investing.com UK
A Look At Viking Therapeutics (VKTX) Valuation As Long Term Gains Contrast Recent Losses - simplywall.st
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - sharewise.com
Viking Therapeutics (NASDAQ:VKTX) Trading Down 6.1%What's Next? - MarketBeat
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - WV News
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing - TechStock²
$VKTX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today - AOL.com
Viking Therapeutics 2026: How Brian Lian Built a $4B Metabolic Fortress - CEO Today
Viking Therapeutics to Present at the 44th Annual J.P. Morgan He - GuruFocus
How A Wall Street Analyst Started A $4 Billion Obesity Drug Company - Forbes
Viking Therapeutics Shares Consolidate as Investors Await Clinical Catalyst - AD HOC NEWS
Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics: A Tale of Clinical Momentum and Financial Strain - AD HOC NEWS
Could Viking Therapeutics Become the Next Eli Lilly? - MSN
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III - sharewise.com
Viking Therapeutics Accelerates Toward Pivotal Obesity Drug Data - AD HOC NEWS
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):